NEUROLOGY 1996;47:46-51
© 1996 American Academy of Neurology
Sumatriptan in clinical practiceA 2-year review of 453 migraine patients
W. Hester Visser, MD,
Rolf H.M. de Vriend, MSc,
Natasja M.W.H. Jaspers, MSc and
Michel D. Ferrari, MD, PhD
From the Department of Neurology, University Hospital, Leiden, The Netherlands.
Received September 11, 1995. Accepted in final form December 28, 1995.
Address correspondence and reprint requests to Dr. Michel D. Ferrari, Department of Neurology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
The long-term and within-patient consistency of the efficacy and tolerability of subcutaneous and oral sumatriptan in migraine was studied by retrospective survey of 2 years with mailed self-administered questionnaires in our neurology outpatient clinic. Subjects were migraine patients with or without aura (N = 869). We measured long-term use of sumatriptan and within-patient consistency and change over time of headache relief, headache recurrence, and chest symptoms after sumatriptan. The questionnaire was returned by 735 (85%) patients; 453 had used sumatriptan for nearly 28,000 attacks during 25 (median) months (92% >1 year). Sumatriptan provided headache relief, mostly within 2 hours, in 85% of patients in at least two-thirds of their attacks. Of all patients, 75% experienced (usually multiple) headache recurrences in at least some and 40% in (nearly) all attacks. Median time to recurrence was 8 to 12 hours (range 1 to 30). Recurrence of aura was reported as well. Over 2 years, efficacy of sumatriptan had waned in 18% of patients (mainly because of increase in headache recurrence) and improved in 12% (mainly because of reduction of headache recurrence or adverse events or increase of headache relief); the number of monthly doses of sumatriptan had increased in 20%, reduced in 35%, and not changed in 45% of patients. Chest symptoms occurred in up to 58% of patients in at least some and in up to 42% of patients in all attacks, causing discontinuation of sumatriptan in 10%. In total, 111 patients (25%) discontinued sumatriptan mainly because of headache recurrence, adverse events, insufficient headache relief, or high price. In most patients, the effects of sumatriptan were consistent within subjects and over time. In most patients, sumatriptan provided rapid headache relief. Multiple headache recurrence was the major limitation. Chest symptoms were frequent but usually not serious if patients were forewarned.
NEUROLOGY 1996;47: 46-51
This article has been cited by other articles:
|
|
|
|
 
A. Krymchantowski, P. Filho, and M. Bigal
Rizatriptan Vs. Rizatriptan Plus Trimebutine for the Acute Treatment of Migraine: A Double-Blind, Randomized, Cross-Over, Placebo-Controlled Study
Cephalalgia,
July 1, 2006;
26(7):
871 - 874.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Goadsby, R. B. Lipton, and M. D. Ferrari
Migraine -- Current Understanding and Treatment
N. Engl. J. Med.,
January 24, 2002;
346(4):
257 - 270.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B Tom, P De Vries, J. Heiligers, E. Willems, E Scalbert, P Delagrange, and P. Saxena
The Lack of Vasoconstrictor Effect of the Pineal Hormone Melatonin in an Animal Model Predictive of Antimigraine Activity
Cephalalgia,
July 1, 2001;
21(6):
656 - 663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. VanDenBrink, R. W. M. van den Broek, R. de Vries, A. J. J. C. Bogers, C. J. J. Avezaat, and P. R. Saxena
Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels
Neurology,
November 28, 2000;
55(10):
1524 - 1530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Maassen VanDenBrink, R. van den Broek, R de Vries, N Upton, A. Parsons, and P. Saxena
The Potential Anti-Migraine Compound SB-220453 does not Contract Human Isolated Blood Vessels or Myocardium; A Comparison with Sumatriptan
Cephalalgia,
July 1, 2000;
20(6):
538 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L Pinessi, I Rainero, L Savi, W Valfre, P Limone, P Calvelli, P Del Rizzo, L Gianotti, M Taliano, E Ghigo, et al.
Effects of Subcutaneous Sumatriptan on Plasma Growth Hormone Concentrations in Migraine Patients
Cephalalgia,
May 1, 2000;
20(4):
223 - 227.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Goadsby, M. D. Ferrari, J. Olesen, L. J. Stovner, J. M. Senard, N. C. Jackson, and P. H. Poole
Eletriptan in acute migraine: A double-blind, placebo-controlled comparison to sumatriptan
Neurology,
January 11, 2000;
54(1):
156 - 156.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Tfelt-Hansen, P. R. Saxena, C. Dahlof, J. Pascual, M. Lainez, P. Henry, H.-C. Diener, J. Schoenen, M. D. Ferrari, and P. J. Goadsby
Ergotamine in the acute treatment of migraine: A review and European consensus
Brain,
January 1, 2000;
123(1):
9 - 18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Gaist
Use and Overuse of Sumatriptan. Pharmacoepidemiological Studies Based on Prescription Register and Interview Data
Cephalalgia,
October 1, 1999;
19(8):
735 - 761.
[PDF]
|
|
|
|
|
|
|
H Gobel, A Heinze, H Stolze, K Heinze-Kuhn, and V Lindner
Open-Labeled Long-Term Study of the Efficacy, Safety, and Tolerability of Subcutaneous Sumatriptan in Acute Migraine Treatment
Cephalalgia,
September 1, 1999;
19(7):
676 - 683.
[Abstract]
[PDF]
|
|
|
|
|
|
|
The Diclofenac-K/Sumatriptan Migraine Study Group
Acute Treatment of Migraine Attacks: Efficacy and Safety of A Nonsteroidal Anti-Inflammatory Drug, Diclofenac-Potassium, in Comparison To Oral Sumatriptan and Placebo
Cephalalgia,
May 1, 1999;
19(4):
232 - 240.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Krymchantowski, M Adriano, and D Fernandes
Tolfenamic Acid Decreases Migraine Recurrence When Used with Sumatriptan
Cephalalgia,
April 1, 1999;
19(3):
186 - 187.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. MaassenVanDenBrink, M. Reekers, W. A. Bax, M. D. Ferrari, and P. R. Saxena
Coronary Side-Effect Potential of Current and Prospective Antimigraine Drugs
Circulation,
July 7, 1998;
98(1):
25 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J GOADSBY
A triptan too far?
J. Neurol. Neurosurg. Psychiatry,
February 1, 1998;
64(2):
143 - 147.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. H. Visser, G. M. Terwindt, S. A. Reines, K. Jiang, C. R. Lines, M. D. Ferrari, and Dutch/US Rizatriptan Study Group
Rizatriptan vs Sumatriptan in the Acute Treatment of Migraine: A Placebo-Controlled, Dose-Ranging Study
Arch Neurol,
November 1, 1996;
53(11):
1132 - 1137.
[Abstract]
[PDF]
|
|
|
|
|
|
|
Long-Term Outcomes with Sumatriptan
Journal Watch Psychiatry,
October 1, 1996;
1996(1001):
17 - 17.
[Full Text]
|
|
|
|
|
|
|
LONG-TERM OUTCOMES WITH SUMATRIPTAN
Journal Watch (General),
August 9, 1996;
1996(809):
1 - 1.
[Full Text]
|
|
|
|
